
QHSLab, Inc.
100
Recent news coverage includes general market and sector developments but no company-specific announcements for QHSLab, Inc.
- Stocks settled lower amid Nvidia rout and higher crude and bond yields, reflecting broader market volatility [N1].
- Wolverine World Wide, Inc. reported third quarter 2026 results, indicating ongoing earnings activity in the sector [N2].
- Glacier Bancorp, Inc. declared a quarterly dividend and announced timing changes for 2027, reflecting dividend policy adjustments [N3].
- Power REIT reported voting results from its 2026 annual meeting of shareholders, indicating governance activity [N4].
- Banco Santander, S.A. called an extraordinary general shareholders' meeting to approve capital increases for an acquisition, reflecting strategic financing moves [N5].
- Allot Ltd. reported third quarter 2026 revenue of $30.6 million, showing operational performance in the tech sector [N6].
- First Mining Gold Corp. reported Q3 2026 financial results and a public offering, indicating capital raising activity [N7].
- Aveanna Healthcare (AVAH) held its Q3 2026 earnings call, providing insights into healthcare sector performance [N8].
QHSLab, Inc. develops and operates a digital health platform designed to integrate with primary care practices' clinical workflows to facilitate identification, documentation, and management of behavioral health conditions and allergic diseases. The platform supports digital health assessments, adaptive logic, risk alerts, automated reporting, and integration with electronic health records. The company also offers the AllergiEnd® allergy diagnostics and treatment service line, including FDA-cleared allergy skin test applicators and immunotherapy treatments. Revenue is generated through recurring subscription and service fees charged to independent, physician-led primary care practices on a per-patient, per-month basis. The company focuses on capital-efficient sales strategies targeting small independent practices and operates within a complex regulatory framework. QHSLab faces competition from multiple healthcare technology providers with greater resources and aims to expand adoption and patient engagement to grow recurring revenues.
QHSLab, Inc. is a digital health company specializing in a platform that enables independent primary care practices to identify and manage behavioral health and allergic conditions through digital screening and follow-up care. The company generates revenue primarily from recurring per-patient, per-month fees charged to medical practices. As of September 30, 2026, QHSLab reported a net loss of $53,145 for the quarter, with cash and cash equivalents of $190,464 and a current ratio of 2.1. The company operates in a heavily regulated healthcare environment and faces competition from various digital health and allergy diagnostic providers. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
QHSLab's integrated digital platform addresses significant unmet needs in behavioral health and allergy management within primary care, enabling scalable screening and follow-up care. The recurring revenue model based on per-patient, per-month fees provides a foundation for steady income growth as adoption expands. The company's capital-efficient sales approach and modular platform design allow for potential expansion into additional clinical domains and deeper workflow integration. The synergy between digital screening and allergy diagnostics could enhance patient outcomes and practice efficiency, supporting sustained engagement and revenue growth.
QHSLab operates in a highly competitive market with numerous better-funded digital health and allergy diagnostic providers, which may limit market penetration and pricing power. The company has a history of net losses and depends on external financing and shareholder support to sustain operations and growth. Regulatory risks are significant given the evolving healthcare laws and FDA oversight of medical mobile applications. The limited scale, small employee base, and focus on independent practices may constrain growth and operational execution. Failure to achieve sustained profitability or secure additional financing could adversely affect business continuity.
QHSLab's moat is based on its integrated digital platform that combines behavioral health screening with allergy diagnostics and treatment services tailored for independent primary care practices. The platform's modular design and workflow integration with electronic health records provide operational efficiencies and support reimbursable clinical activities. The company's focus on underserved independent practices and its combined digital and diagnostic approach create a differentiated offering. However, competition from larger, better-resourced healthcare technology and allergy diagnostic providers, as well as regulatory complexities, limit the moat's defensibility.
• Financial Sustainability Risk: The company has a history of net losses and depends on additional financing to fund operations and growth. Failure to secure financing or generate consistent positive cash flow could impair business continuity [S1].
• Regulatory Risk: QHSLab operates in a heavily regulated healthcare environment subject to laws such as Stark Law, Anti-Kickback Act, HIPAA, False Claims Act, and FDA guidance on medical mobile applications. Non-compliance or regulatory changes could adversely impact operations [S1].
• Competitive Risk: The company faces intense competition from healthcare technology and allergy diagnostic providers with greater financial, technical, and marketing resources, which may limit market share and growth [S1].
• Operational Risk: Limited employee base and reliance on independent consultants may constrain the company's ability to scale sales, marketing, and product development effectively [S1].
Business trends: Increasing adoption of digital health platforms in primary care with focus on behavioral health and allergy management; regulatory environment evolving with healthcare technology oversight.
Execution milestones: Expanding customer base among independent primary care practices; enhancing platform capabilities and integration; sustaining recurring revenue growth.
Key risks: Financial sustainability due to historical losses and financing dependence; regulatory compliance challenges; competitive pressures from larger healthcare technology providers.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- QHSLab, Inc. is a digital health company focused on enabling independent primary care practices to identify, document, and manage underdiagnosed and undertreated behavioral health conditions through workflow-integrated digital screening and non-face-to-face follow-up care [S1].
- The company generates revenue primarily through recurring per-patient, per-month fees paid by participating medical practices for access to and use of its digital platform and associated services [S1].
- The platform supports reimbursable clinical activities including digital assessments, asynchronous interactions, and care management services, which are billed by practices according to payer rules [S1].
- QHSLab offers an allergy diagnostics and treatment service line under the AllergiEnd® brand, designed to operate synergistically with the digital platform to enable primary care practices to identify and manage allergic disease [S1].
- The digital platform functions as an extension of a medical practice's clinical workflow, supporting structured screening, automated documentation, digital follow-up, and integration with electronic health records (EHR) [S1].
- Core platform capabilities include adaptive assessment logic, imminent risk alerts (e.g., suicide risk), automated report generation, and support for non-face-to-face care management workflows [S1].
- The platform is modular and extensible, allowing addition of new clinical domains and assessment variables over time [S1].
- The care model is structured around a repeatable patient journey applied across large populations, facilitating health care delivery over extended periods focusing on full spectrum health [S1].
- Revenue model consists of recurring subscription and service fees charged to medical practices on a per-patient, per-month basis; the company does not bill patients or payers directly [S1].
- AllergiEnd® products include FDA-cleared, disposable allergy skin test applicators and test trays for office-based use, with training and operational support provided to practices [S1].
- Allergy treatment includes allergen immunotherapy via subcutaneous injections or sublingual oral drops, prescribed by physicians following diagnostic confirmation [S1].
- Target customers are independent, physician-led primary care practices with one to ten providers, billing Medicare and/or commercial insurance [S1].
- Sales strategy is focused and capital-efficient, engaging customers through existing relationships, referrals, and targeted direct sales and marketing [S1].
- The healthcare industry is shifting toward preventive care, population health management, and non-face-to-face clinical services, with increasing reimbursement recognition for digital assessments and care management [S1].
- Competition includes point-solution digital health vendors, behavioral health platforms, chronic care management software, EHR-embedded tools, and allergy diagnostic device manufacturers; many competitors have greater resources [S1].
- Near-term growth strategy focuses on expanding adoption among independent primary care practices, increasing patient enrollment per practice, and supporting recurring revenue growth through sustained patient engagement [S1].
- Longer-term growth opportunities may include expansion into additional clinical domains, deeper workflow integration, and broader strategic partnerships, subject to capital and regulatory considerations [S1].
- The company had twelve full-time employees as of March 30, 2026, engaged in direct sales and operations, supplemented by independent consultants [S1].
- The company reported net income of -$53,145 for the quarter ended September 30, 2026, with zero reported basic and diluted EPS for the same period [S2].
- As of September 30, 2026, QHSLab had cash and cash equivalents of $190,464 and current assets of $519,108, with current liabilities of $247,114, resulting in a current ratio of 2.1 and a cash ratio of 0.77 [S2].
- The company has historically incurred net losses but achieved net income in 2025 partly due to a net gain on extinguishment of debt; it depends on financing to fund operations and growth [S1].
- The company is subject to extensive healthcare regulations including Stark Law, Anti-Kickback Act, HIPAA, False Claims Act, and FDA guidance on medical mobile applications, with potential regulatory risks [S1].
- The company does not provide medical diagnoses or treatment decisions but supports licensed healthcare professionals in clinical services [S1].
- As of November 12, 2026, the company had 15,032,788 shares of common stock outstanding [S2].
Generated 2026-11-13
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Stocks Settle Lower on Nvidia Rout and Higher Crude and Bond Yields | https://www.nasdaq.com/articles/stocks-settle-lower-nvidia-rout-and-higher-crude-and-bond-yields
- N2 | 2026-11-13 | www.nasdaq.com | Wolverine World Wide, Inc. Reports Third Quarter 2026 Results | https://www.nasdaq.com/articles/wolverine-world-wide-inc-reports-third-quarter-2026-results
- N3 | 2026-11-13 | www.nasdaq.com | Glacier Bancorp, Inc. Declares Quarterly Dividend of $0.35 Per Share and Announces Timing Change for 2027 | https://www.nasdaq.com/articles/glacier-bancorp-inc-declares-quarterly-dividend-035-share-and-announces-timing-change-2027
- N4 | 2026-11-13 | www.nasdaq.com | Power REIT Reports Voting Results from 2026 Annual Meeting of Shareholders | https://www.nasdaq.com/articles/power-reit-reports-voting-results-2026-annual-meeting-shareholders
- N5 | 2026-11-13 | www.nasdaq.com | Banco Santander, S.A. Calls Extraordinary General Shareholders' Meeting on 15 December 2026 to Approve Capital Increases for Santander Brazil Acquisition | https://www.nasdaq.com/articles/banco-santander-sa-calls-extraordinary-general-shareholders-meeting-15-december-2026
- N6 | 2026-11-13 | www.nasdaq.com | Allot Ltd. Reports Third Quarter 2026 Revenue of $30.6 million | https://www.nasdaq.com/articles/allot-ltd-reports-third-quarter-2026-revenue-306-million
- N7 | 2026-11-13 | www.nasdaq.com | First Mining Gold Corp. Reports Q3 2026 Financial Results and $57,506,000 Public Offering | https://www.nasdaq.com/articles/first-mining-gold-corp-reports-q3-2026-financial-results-and-57506000-public-offering
- N8 | 2026-11-12 | www.nasdaq.com | Aveanna Healthcare (AVAH) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/aveanna-healthcare-avah-q3-2026-earnings-call-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


